TotalMarketCap

Taysha Gene Therapies

TSHANasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.347 B

$4.14 -5.16%

Close of 6 Nov 2026

As of 6 Nov 2026, Taysha Gene Therapies (TSHA) has a market capitalization of $1.35B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$9.77M

#3136 by revenue

Earnings

-$109.0M

Loss-making

Shares outstanding

325,833,545

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #41Lycia TherapeuticsLYCA$1.50B
  2. #42ImmunocoreIMCR$1.47B
  3. #43Taysha Gene TherapiesTSHA$1.35B
  4. #44Inhibrx BiosciencesINBX$1.18B
  5. #45Vor BiopharmaVOR$1.15B

What if Taysha Gene Therapies were worth as much as…

Open the what-if tool →

Gold $28.2T

$86,660.43

Per share 20,958× higher

Bitcoin $1.53T

$4,689.04

Per share 1,134× higher

Apple $5.02T

$15,393.70

Per share 3,723× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Taysha Gene Therapies are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.